Levetiracetam Sustained-release Granules(Shanghai Anbison Lab)

左乙拉西坦缓释颗粒(上海安必生制药)

Report date: 2025/04/21 14:49:12

Base Information

Drug NameLevetiracetam Sustained-release Granules(Shanghai Anbison Lab)
Drug Alias Name左旋乙拉西坦左乙拉西坦缓释颗粒(2.2改良型)N003CGN003-CG
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSynaptic vesicle glycoprotein 2A modulators
TargetsSynaptic vesicle glycoprotein 2A
Therapy Area/IndicationsEpilepsy
Global Approved IndicationsEpilepsy
Approved Indications in ChinaEpilepsy
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/24
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Anbison Lab Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsEpilepsy
Inactive IndicationsN/A

Other Information

ATC CodeN/A